AMPA receptor-mediated neuronal death in sporadic ALS

Shin Kwak1, Takuto Hideyama, Takenari Yamashita

  • 1Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo. kwak-tky@umin.ac.jp

Insights

RNA editing of the GluR2 gene is reduced in motor neurons of sporadic amyotrophic lateral sclerosis (ALS) patients. This deficit in adenosine deaminase acting on RNA 2 (ADAR2) activity may cause motor neuron death in ALS.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor excitotoxicity is implicated in motor neuron death in amyotrophic lateral sclerosis (ALS).
  • RNA editing of GluR2 mRNA at the Q/R site is crucial for AMPA receptor function and calcium permeability.

Purpose of the Study:

  • To investigate the role of RNA editing in sporadic ALS pathogenesis.
  • To determine if alterations in GluR2 mRNA editing and ADAR2 expression are specific to motor neurons in sporadic ALS.

Main Methods:

  • Analysis of autopsy-obtained spinal motor neurons and cerebellar Purkinje cells from sporadic ALS patients and controls.
  • Quantification of ADAR2 expression levels in spinal cord tissue.

Main Results:

  • Decreased RNA editing of GluR2 mRNA at the Q/R site was observed in motor neurons of sporadic ALS patients, but not in cerebellar neurons or in other neurodegenerative diseases.
  • ADAR2 expression levels were significantly reduced in the spinal ventral gray matter of sporadic ALS patients compared to controls.
  • The observed molecular changes were specific to motor neurons in sporadic ALS.

Conclusions:

  • Underactivity of ADAR2 in motor neurons leads to deficient GluR2 Q/R site-editing, increasing the proportion of calcium-permeable AMPA receptors.
  • This process is a likely initiator of motor neuron death in sporadic ALS.
  • Restoring ADAR2 activity in motor neurons presents a potential therapeutic strategy for sporadic ALS.

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...